npj Vaccines
A multidisciplinary journal that is dedicated to publishing the finest and high-quality research and development on human and veterinary vaccines.
Clinical Testing of the cAd3-Ebola and MVA-EbolaZ vaccines
In two parallel phase I/Ib trials, both cAd3-vectored Ebola and MVA-EbolaZ vaccines were safe and well tolerated in healthy adults recruited from the United States and Uganda. The vaccines were immunogenic and elicited durable antibody responses.
Neoantigen Vaccine Nanoformulations based on Chemically Synthesized Minimal mRNA (CmRNA): Small Molecules, Big Impact
Our npj Vaccines article unveils a prospective breakthrough in personalized cancer immunotherapy, featuring Chemically Synthesized Minimal mRNA (CmRNA) in Lipid-Polymer Hybrid Nanoparticles (LPPs). This idea not only answers ongoing research needs but propels a paradigm shift in cancer treatment.
Bridging the gap: immunobridging large-scale efficacy data of a tetravalent dengue vaccine (TAK-003) from children and teenagers to adults
Behind the Paper : LeFevre, I., et al. Bridging the immunogenicity of a tetravalent dengue vaccine (TAK-003) from children and adolescents to adults. NPJ Vaccines 8, 75 (2023).
Quadrivalent self-amplifying mRNA vaccines generate protective antibody and cell-mediated immunity to influenza
Self-amplifying mRNA is a promising platform for vaccine development, highlighted by our group's recent publication in npj Vaccines showing that a quadrivalent bicistronic sa-mRNA vaccine can generate protective immunity to both HA and NA from 4 influenza strains when formulated in a single vaccine.
Discovery of a natural IgA human monoclonal antibody against Mtb protein LpqH and its significance in TB prophylaxis
The discovery of a protective natural IgA human monoclonal antibody against LpqH, a major virulence factor in Mtb pathogenesis, from a naturally exposed asymptomatic donor, opens new avenues in TB vaccine development and prophylaxis.
Full-length MSP1 as a malaria vaccine: is there hope?
Successful immunisation studies in monkeys based on MSP1 involved the use of the full-length protein as a malaria vaccine. However, unsuccessful human trials only tested MSP1 subunits. We explore the potential of SumayaVac-1 to broadly stimulate immune mechanisms associated with protection.